The development of methods to predict the apoptotic and cytostatic response after therapy of solid tumours became an important aspect of his professional life. His growing interest in the subject allows him to establish in 2001 HistoGeneX, a company that specializes in development of tissue biomarkers and their use in the monitoring of cancer treatment.
HistoGeneX creates the bridge between research and clinical trial testing. The company is actively involved in the development of predictive biomarkers associated with cancer treatment, making the company a partner of choice in discovery and clinical trial studies. The company employs currently over 50 highly skilled staff and is growing.